Loos Carolin, Coccia Margherita, Didierlaurent Arnaud M, Essaghir Ahmed, Fallon Jonathan K, Lauffenburger Douglas, Luedemann Corinne, Michell Ashlin, van der Most Robbert, Zhu Alex Lee, Alter Galit, Burny Wivine
The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
GSK, Rixensart, Belgium.
NPJ Vaccines. 2023 Mar 8;8(1):34. doi: 10.1038/s41541-023-00613-1.
The mechanisms by which antibodies confer protection vary across vaccines, ranging from simple neutralization to functions requiring innate immune recruitment via Fc-dependent mechanisms. The role of adjuvants in shaping the maturation of antibody-effector functions remains under investigated. Using systems serology, we compared adjuvants in licensed vaccines (AS01/AS01/AS03/AS04/Alum) combined with a model antigen. Antigen-naive adults received two adjuvanted immunizations followed by late revaccination with fractional-dosed non-adjuvanted antigen ( NCT00805389 ). A dichotomy in response quantities/qualities emerged post-dose 2 between AS01/AS01/AS03 and AS04/Alum, based on four features related to immunoglobulin titers or Fc-effector functions. AS01 and AS03 induced similar robust responses that were boosted upon revaccination, suggesting that memory B-cell programming by the adjuvanted vaccinations dictated responses post non-adjuvanted boost. AS04 and Alum induced weaker responses, that were dissimilar with enhanced functionalities for AS04. Distinct adjuvant classes can be leveraged to tune antibody-effector functions, where selective vaccine formulation using adjuvants with different immunological properties may direct antigen-specific antibody functions.
抗体提供保护的机制因疫苗而异,从简单的中和作用到通过Fc依赖性机制招募先天免疫所需的功能。佐剂在塑造抗体效应功能成熟过程中的作用仍在研究中。我们使用系统血清学方法,比较了已获许可疫苗(AS01/AS01/AS03/AS04/明矾)中的佐剂与一种模型抗原的组合。未接触过抗原的成年人接受两次含佐剂免疫接种,随后用分剂量的无佐剂抗原进行后期再接种(NCT00805389)。基于与免疫球蛋白滴度或Fc效应功能相关的四个特征,在第2剂接种后,AS01/AS01/AS03与AS04/明矾之间出现了反应量/质的二分法。AS01和AS03诱导了相似的强烈反应,再接种后反应增强,这表明含佐剂疫苗接种对记忆B细胞的编程决定了无佐剂加强接种后的反应。AS04和明矾诱导的反应较弱,且AS04的功能增强有所不同。可以利用不同类别的佐剂来调节抗体效应功能,使用具有不同免疫特性的佐剂进行选择性疫苗配方可能会指导抗原特异性抗体功能。